RxDoctor Payments Data

Ahmad El Alayli, MD

Internal Medicine · Roswell, NMNPI 1679060099

Payments from drug & device makers

$448in general payments, 2019–2025

Across 24 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$144
  • Daiichi Sankyo Inc.$72
  • AstraZeneca$56
  • AbbVie$35
  • Merck$34
  • Sobi, Inc$23
  • plus $84 from 5 others

What the payments were for

  • Food & beverage$448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$448 in reported general payments places this provider in the 75th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$357,999
Medicare patients
586
Services billed
11,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin94$134,898
OzempicSemaglutide77$101,945
TrulicityDulaglutide44$71,817
EliquisApixaban57$56,089
JanuviaSitagliptin Phosphate34$46,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$43,541
XareltoRivaroxaban20$26,958
MyrbetriqMirabegron14$18,809
JanumetSitagliptin Phos/Metformin Hcl13$17,652
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog50$17,482
Repatha SureclickEvolocumab16$15,449
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,756
Breo ElliptaFluticasone/Vilanterol18$10,462
Advair HfaFluticasone Propion/Salmeterol16$10,383
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$9,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$34$64,38947 claims
AstraZenecaBreztri Aerosphere, Symbicort$56$18,65934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Roswell

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →